Mexidol, 125 mg 50 pcs.

Mexidol® is an inhibitor of free radical processes, membranoprotector with antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects. The preparation increases resistance to the effects of different damaging factors (shock, hypoxia and ischemia, cerebral circulation disorders, intoxication with alcohol and antipsychotic drugs (neuroleptics).

Mexidol® action mechanism is based on its antioxidant, antihypoxant and membranoprotective actions. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces membrane viscosity and increases its fluidity. Mexidol® modulates the activity of membrane-bound enzymes (calcium independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which increases their ability to bind to ligands, maintains structural and functional organization of biomembranes, transports neurotransmitters and improves synaptic transmission.

Mexidol® increases the content of dopamine in the brain. It causes enhancement of compensatory activation of aerobic glycolysis and reduction of the degree of inhibition of oxidative processes in the Krebs cycle under hypoxia with increase of ATP and creatine phosphate content, activation of energy-synthesizing functions of mitochondria and stabilization of cell membranes.

The drug improves metabolism and blood supply of the brain, improves microcirculation and blood rheology, reduces platelet aggregation. Stabilizes membrane structures of blood cells (erythrocytes and platelets) in hemolysis. It has hypolipidemic effect, reduces the content of total cholesterol and low-density lipoproteins.

The anti-stressor effect is shown in normalization of post-stress behavior, somatovegetative disorders, restoration of sleep-wake cycles, disturbed learning and memory processes, decrease of dystrophic and morphological changes in different structures of the brain.

Mexidol® has a pronounced anti-toxic effect during withdrawal syndrome. It eliminates neurological and neurotoxic manifestations of acute alcohol intoxication, restores disturbances of behavior, vegetative functions and is able to remove cognitive disorders caused by prolonged intake of ethanol and its withdrawal. Under the influence of Mexidol® the effects of tranquilizers, neuroleptics, antidepressants, hypnotics and anticonvulsants are increased, which allows reducing their dosages and side effects. Mexidol® improves functional state of ischemic myocardium. In conditions of coronary insufficiency it increases collateral blood supply of ischemic myocardium, promotes preservation of integrity of cardiomyocytes and maintenance of their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction.

Pharmacokinetics

Intake

It is rapidly absorbed when taken orally. Maximum concentration at doses of 400 to 500 mg is 3.5 to 4.0 µg/mL.

Distribution

The drug is rapidly distributed in organs and tissues. Mean time of retention of the drug in the body when administered orally is 4.9 – 5.2 h. It is metabolized in the liver by glucuron conjugation. Five metabolites have been identified: 3-oxypyridine phosphate – formed in the liver and degraded to phosphoric acid and 3-oxypyridine with the assistance of alkaline phosphatase; the 2nd metabolite – pharmacologically active, formed in large amounts and found in the urine 1-2 days after administration; the 3rd – excreted in large amounts in the urine; the 4th and 5th – glucuron conjugates. T1/2 when administered orally is 2.0 – 2.6 h. </Excretion

Extracted rapidly in the urine mainly as metabolites and in insignificant amounts unchanged. Excretion is most intense during the first 4 hours after drug administration. Indexes of urinary excretion of unchanged drug and metabolites have individual variability.

Indications

The consequences of acute cerebral circulatory disorders, including after transient ischemic attacks, in the subcompensation phase as a preventive course;

mild traumatic brain injury, consequences of brain injuries;

encephalopathies of various genesis (discirculatory, dysmetabolic, post-traumatic, mixed);

dietary dystonia syndrome;

mild cognitive disorders of atherosclerotic genesis;

anxiety disorders in neurotic and neurosis-like conditions;

states after acute intoxication with antipsychotic agents;

Asthenic conditions, as well as for the prevention of the development of somatic diseases under the influence of extreme factors and loads;

exposure to extreme (stressful) factors.

ischemic heart disease as part of the complex therapy;

management of withdrawal syndrome in alcoholism with predominant neurosis and vegetative-vascular disorders, post-abstinence disorders

Active ingredient

Composition

Active ingredient:

Ethylmethylhydroxypyridine succinate (2-ethyl-6-methyl-3-hydroxypyridine succinate) – 125.0 mg

Associates:

Lactose monohydrate – 97.5 mg,

povidone – 25.0 mg,

magnesium stearate – 2.50 mg

Film coating:

Opadray II white 33G28435 – 7.5 mg (hypromellose – 3.0 mg, titanium dioxide – 1.875 mg, lactose monohydrate – 1.575 mg, polyethylene glycol (macrogol) – 0.6 mg, triacetin – 0.45 mg)

How to take, the dosage

Manual administration and dosage regimen depending on symptoms

Ingestion 125-250 mg 3 times per day; maximum daily dose – 800 mg (6 tablets). Duration of treatment is 2-6 weeks; for relief of alcohol withdrawal – 5-7 days. Treatment is discontinued gradually, reducing the dose over 2-3 days.

The initial dose is 125-250 mg (1-2 tablets) 1-2 times a day with gradual increase until therapeutic effect; the maximum daily dose is 800 mg (6 tablets).

The duration of therapy in patients with CHD is at least 1.5-2 months. Repeated courses (as recommended by the doctor) are advisable in the spring and autumn periods.

Interaction

Mexidol® is combined with all drugs used for the treatment of somatic diseases.

When used together, Mexidol® increases the effect of benzodiazepine derivatives, antidepressants, anxiolytics, anti-Parkinsonian and anticonvulsants.

Mexidol® reduces the toxic effects of ethanol.

Special Instructions

Precautions when taking the drug

Mexidol® can be combined with all drugs used to treat somatic diseases.

Pediatric use

Mexidol® is not indicated for children because of insufficient study of the drug.

Impact on ability to drive vehicles and other mechanisms requiring increased concentration

When using the drug, caution must be exercised while driving vehicles and engaging in other potentially dangerous activities requiring increased concentration and quick psychomotor reactions.

Interaction with alcohol

Mexidol® decreases toxic effects of ethanol.

Prescription conditions

The drug is available with a prescription.

Contraindications

The contraindication to the use of Mexidol is:

In relation to the insufficient study of the drug action:

Side effects

When using the drug:

Digestive system: Individual adverse reactions of a dyspeptic or dyspeptic nature may occur.

Others: allergic reactions are possible.

Overdose

In case of overdose, drowsiness may develop.

Pregnancy use

Strictly controlled clinical studies of safety of Mexidol® use during pregnancy and lactation have not been conducted.

Similarities